Informed Therapeutic Microbiome Modulation for Post-Infectious Irritable Bowel Syndrome: Pilot Experience of a Microbiome Clinic

W. Fusco; Flavio De Maio; Serena Porcari; Andrea Severino; Daniele Salvi; S. Piccirelli; C. Ferrari; A. Sibilla; G. Quaranta; Luca Masucci; Giovanni Cammarota; Maurizio Sanguinetti; Antonio Gasbarrini; Gianluca Ianiro

doi:10.3390/nu18030490

Informed Therapeutic Microbiome Modulation for Post-Infectious Irritable Bowel Syndrome: Pilot Experience of a Microbiome Clinic

W. Fusco
, Flavio De Maio
, Serena Porcari
, Andrea Severino
, Daniele Salvi
, S. Piccirelli
, C. Ferrari
, A. Sibilla
, G. Quaranta
, Luca Masucci
, Giovanni Cammarota
, Maurizio Sanguinetti
, Antonio Gasbarrini
, Gianluca Ianiro^*

^*Corresponding author

Fondazione Poliambulanza Istituto Ospedaliero

Research output: Contribution to journal › Article

Abstract

Background: Untargeted microbiome modulation has achieved conflicting results in post-infectious irritable bowel syndrome (PI-IBS). Methods: In a case–control study of PI-IBS patients, cases received targeted microbial modulation informed by microbiome profiling, while controls were managed by standard therapy. Treatment response was defined as a decrease in IBS-symptom severity scale (IBS-SSS) ≥50 points. Results: All thirteen cases (100%) and 11/20 controls (55%) experienced treatment response (p < 0.0001). The mean IBS-SSS score after treatments was 163 in cases and 231 in controls (p = 0.01). Conclusions: Based on our preliminary results, therapeutic microbiome modulation might be a promising strategy for PI-IBS. Further studies are needed to clarify its role.

Original language	English
Pages (from-to)	N/A-N/A
Journal	Nutrients
Volume	18
Issue number	3
DOIs	https://doi.org/10.3390/nu18030490
Publication status	Published - 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Food Science
Nutrition and Dietetics

Keywords

irritable bowel syndrome
microbiome
personalized medicine
precision medicine

Access to Document

10.3390/nu18030490

Cite this

Fusco, W., De Maio, F., Porcari, S., Severino, A., Salvi, D., Piccirelli, S., Ferrari, C., Sibilla, A., Quaranta, G., Masucci, L., Cammarota, G., Sanguinetti, M., Gasbarrini, A., & Ianiro, G. (2026). Informed Therapeutic Microbiome Modulation for Post-Infectious Irritable Bowel Syndrome: Pilot Experience of a Microbiome Clinic. Nutrients, 18(3), N/A-N/A. https://doi.org/10.3390/nu18030490

@article{a6722509c876478ab392bc6ea79d25f8,

title = "Informed Therapeutic Microbiome Modulation for Post-Infectious Irritable Bowel Syndrome: Pilot Experience of a Microbiome Clinic",

abstract = "Background: Untargeted microbiome modulation has achieved conflicting results in post-infectious irritable bowel syndrome (PI-IBS). Methods: In a case{\textendash}control study of PI-IBS patients, cases received targeted microbial modulation informed by microbiome profiling, while controls were managed by standard therapy. Treatment response was defined as a decrease in IBS-symptom severity scale (IBS-SSS) ≥50 points. Results: All thirteen cases (100\%) and 11/20 controls (55\%) experienced treatment response (p < 0.0001). The mean IBS-SSS score after treatments was 163 in cases and 231 in controls (p = 0.01). Conclusions: Based on our preliminary results, therapeutic microbiome modulation might be a promising strategy for PI-IBS. Further studies are needed to clarify its role.",

keywords = "irritable bowel syndrome, microbiome, personalized medicine, precision medicine, irritable bowel syndrome, microbiome, personalized medicine, precision medicine",

author = "W. Fusco and \{De Maio\}, Flavio and Serena Porcari and Andrea Severino and Daniele Salvi and S. Piccirelli and C. Ferrari and A. Sibilla and G. Quaranta and Luca Masucci and Giovanni Cammarota and Maurizio Sanguinetti and Antonio Gasbarrini and Gianluca Ianiro",

year = "2026",

doi = "10.3390/nu18030490",

language = "English",

volume = "18",

pages = "N/A--N/A",

journal = "Nutrients",

issn = "2072-6643",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "3",

}

Fusco, W, De Maio, F, Porcari, S , Severino, A , Salvi, D, Piccirelli, S, Ferrari, C, Sibilla, A, Quaranta, G, Masucci, L , Cammarota, G , Sanguinetti, M , Gasbarrini, A & Ianiro, G 2026, 'Informed Therapeutic Microbiome Modulation for Post-Infectious Irritable Bowel Syndrome: Pilot Experience of a Microbiome Clinic', Nutrients, vol. 18, no. 3, pp. N/A-N/A. https://doi.org/10.3390/nu18030490

TY - JOUR

T1 - Informed Therapeutic Microbiome Modulation for Post-Infectious Irritable Bowel Syndrome: Pilot Experience of a Microbiome Clinic

AU - Fusco, W.

AU - De Maio, Flavio

AU - Porcari, Serena

AU - Severino, Andrea

AU - Salvi, Daniele

AU - Piccirelli, S.

AU - Ferrari, C.

AU - Sibilla, A.

AU - Quaranta, G.

AU - Masucci, Luca

AU - Cammarota, Giovanni

AU - Sanguinetti, Maurizio

AU - Gasbarrini, Antonio

AU - Ianiro, Gianluca

PY - 2026

Y1 - 2026

N2 - Background: Untargeted microbiome modulation has achieved conflicting results in post-infectious irritable bowel syndrome (PI-IBS). Methods: In a case–control study of PI-IBS patients, cases received targeted microbial modulation informed by microbiome profiling, while controls were managed by standard therapy. Treatment response was defined as a decrease in IBS-symptom severity scale (IBS-SSS) ≥50 points. Results: All thirteen cases (100%) and 11/20 controls (55%) experienced treatment response (p < 0.0001). The mean IBS-SSS score after treatments was 163 in cases and 231 in controls (p = 0.01). Conclusions: Based on our preliminary results, therapeutic microbiome modulation might be a promising strategy for PI-IBS. Further studies are needed to clarify its role.

AB - Background: Untargeted microbiome modulation has achieved conflicting results in post-infectious irritable bowel syndrome (PI-IBS). Methods: In a case–control study of PI-IBS patients, cases received targeted microbial modulation informed by microbiome profiling, while controls were managed by standard therapy. Treatment response was defined as a decrease in IBS-symptom severity scale (IBS-SSS) ≥50 points. Results: All thirteen cases (100%) and 11/20 controls (55%) experienced treatment response (p < 0.0001). The mean IBS-SSS score after treatments was 163 in cases and 231 in controls (p = 0.01). Conclusions: Based on our preliminary results, therapeutic microbiome modulation might be a promising strategy for PI-IBS. Further studies are needed to clarify its role.

KW - irritable bowel syndrome

KW - microbiome

KW - personalized medicine

KW - precision medicine

KW - irritable bowel syndrome

KW - microbiome

KW - personalized medicine

KW - precision medicine

UR - https://publicatt.unicatt.it/handle/10807/338241

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=105029950710&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105029950710&origin=inward

U2 - 10.3390/nu18030490

DO - 10.3390/nu18030490

M3 - Article

SN - 2072-6643

VL - 18

SP - N/A-N/A

JO - Nutrients

JF - Nutrients

IS - 3

ER -

Informed Therapeutic Microbiome Modulation for Post-Infectious Irritable Bowel Syndrome: Pilot Experience of a Microbiome Clinic

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this